Find out the latest articles about EDGC.
EDGC announced on Feb 28 that it recorded sales of 21.5 billion won and operating profit of 6.8 billion won in 2018.
Sang-chul Shin, co-CEO of EDGC, said, "The growth of three-digit sales (KRW 21.5 billion) in 5 years from its sales of KRW 3.2 billion in 2017
is the result of the expansion of business and customers’ visible needs for the clinical genomics services."
In addition, “Technical transfer of EDGC's genetic analysis services to overseas has also contributed to the sales increase,” Shin said.